Skip to main content
Clinical Trials/NL-OMON48963
NL-OMON48963
Recruiting
Not Applicable

Stratifying Cystic Fibrosis Patients Based on Intestinal Organoid Response To Different CFTR-modulators - Part 1 HIT-CF project: Organoid Study

niversitair Medisch Centrum Utrecht0 sites75 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
75
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female with confirmed diagnosis of CF. The subject must have of the following:
  • o One or more characteristic phenotypic features, such as chronic cough and sputum production, persistent chest radiograph abnormalities, or airway obstruction manifested by wheezing and air trapping; or a history of CF in a
  • sibling ; or a positive new\-born screening test result;
  • 2\. An increased sweat chloride concentration (above 60 mmol/L) by pilocarpine iontophoresis (documented in patient records)
  • 3\. Adult age\* on the date of informed consent for biopsy taking. Younger patients will not be included due to extensive and long\-term safety data needed before a trial in younger paediatric patients is considered safe.
  • \*16 or 18 years depending on country\-specific ethical regulations
  • 4\. Subject will sign and date an informed consent form (ICF).

Exclusion Criteria

  • 1\. Subject has at least one of the following CFTR\-mutations:
  • 508del, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H, A455E, 3849\+10kbC\>T
  • 2\. Subject has a combination of any two (2\) of the following mutations:
  • G542X, 1717\-1G\>A, 621\+1G\>T, 3120\+1G\>A, 1898\+1G\-\>A, CFTRdele2,3 and 2183AA\-\>G
  • 3\. History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might pose an additional risk in potentially administering study drug to the subject if he or she enters the subsequent clinical study. For example, a history of cirrhosis with portal hypertension.
  • 4\. History of lung transplantation.

Outcomes

Primary Outcomes

Not specified

Similar Trials